vs
阿斯利康（AZN）与China SXT Pharmaceuticals, Inc.（SXTC）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是China SXT Pharmaceuticals, Inc.的17428.8倍（$14.5B vs $829.5K）。阿斯利康净利率更高（16.9% vs -96.8%，领先113.7%）。阿斯利康同比增速更快（11.7% vs 0.0%）
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
中国SXT药业是一家聚焦中国本土市场的制药企业，主要从事中药类处方药、非处方药物及营养保健品的研发、生产与销售，服务覆盖临床医疗机构与大众健康消费两大板块。
AZN vs SXTC — 直观对比
营收规模更大
AZN
是对方的17428.8倍
$829.5K
营收增速更快
AZN
高出11.7%
0.0%
净利率更高
AZN
高出113.7%
-96.8%
损益表 — Q2 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $14.5B | $829.5K |
| 净利润 | $2.4B | $-802.6K |
| 毛利率 | 82.9% | 16.2% |
| 营业利润率 | 24.3% | -76.9% |
| 净利率 | 16.9% | -96.8% |
| 营收同比 | 11.7% | 0.0% |
| 净利润同比 | 27.0% | 0.0% |
| 每股收益（稀释后） | $1.57 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZNSXTC
| Q3 25 | — | $829.5K | ||
| Q2 25 | $14.5B | — | ||
| Q3 24 | — | $829.5K | ||
| Q2 24 | $12.9B | — | ||
| Q3 23 | — | $939.6K | ||
| Q2 23 | $11.4B | — | ||
| Q3 22 | — | $1.2M | ||
| Q2 22 | $10.8B | — |
净利润AZNSXTC
| Q3 25 | — | $-802.6K | ||
| Q2 25 | $2.4B | — | ||
| Q3 24 | — | $-802.6K | ||
| Q2 24 | $1.9B | — | ||
| Q3 23 | — | $-9.7M | ||
| Q2 23 | $1.8B | — | ||
| Q3 22 | — | $-1.5M | ||
| Q2 22 | $360.0M | — |
毛利率AZNSXTC
| Q3 25 | — | 16.2% | ||
| Q2 25 | 82.9% | — | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | 83.1% | — | ||
| Q3 23 | — | 30.7% | ||
| Q2 23 | 82.8% | — | ||
| Q3 22 | — | 7.4% | ||
| Q2 22 | 72.2% | — |
营业利润率AZNSXTC
| Q3 25 | — | -76.9% | ||
| Q2 25 | 24.3% | — | ||
| Q3 24 | — | -76.9% | ||
| Q2 24 | 21.2% | — | ||
| Q3 23 | — | -995.0% | ||
| Q2 23 | 21.5% | — | ||
| Q3 22 | — | -95.2% | ||
| Q2 22 | 5.0% | — |
净利率AZNSXTC
| Q3 25 | — | -96.8% | ||
| Q2 25 | 16.9% | — | ||
| Q3 24 | — | -96.8% | ||
| Q2 24 | 14.9% | — | ||
| Q3 23 | — | -1032.0% | ||
| Q2 23 | 15.9% | — | ||
| Q3 22 | — | -123.7% | ||
| Q2 22 | 3.3% | — |
每股收益（稀释后）AZNSXTC
| Q3 25 | — | — | ||
| Q2 25 | $1.57 | — | ||
| Q3 24 | — | $-0.25 | ||
| Q2 24 | $1.24 | — | ||
| Q3 23 | — | $-19.34 | ||
| Q2 23 | $1.17 | — | ||
| Q3 22 | — | $-14.61 | ||
| Q2 22 | $0.23 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1B | $18.1M |
| 总债务越低越好 | — | $105.0K |
| 股东权益账面价值 | $44.8B | $15.4M |
| 总资产 | $112.4B | $21.7M |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AZNSXTC
| Q3 25 | — | $18.1M | ||
| Q2 25 | $7.1B | — | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | $6.9B | — | ||
| Q3 23 | — | $11.5M | ||
| Q2 23 | $5.7B | — | ||
| Q3 22 | — | $3.0M | ||
| Q2 22 | $4.8B | — |
总债务AZNSXTC
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $106.6K | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
股东权益AZNSXTC
| Q3 25 | — | $15.4M | ||
| Q2 25 | $44.8B | — | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | $39.6B | — | ||
| Q3 23 | — | $5.1M | ||
| Q2 23 | $37.4B | — | ||
| Q3 22 | — | $14.5M | ||
| Q2 22 | $36.0B | — |
总资产AZNSXTC
| Q3 25 | — | $21.7M | ||
| Q2 25 | $112.4B | — | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | $104.3B | — | ||
| Q3 23 | — | $14.6M | ||
| Q2 23 | $96.5B | — | ||
| Q3 22 | — | $22.2M | ||
| Q2 22 | $96.6B | — |
负债/权益比AZNSXTC
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q3 23 | — | 0.02× | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.8M |
| 自由现金流率自由现金流/营收 | — | -216.2% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AZNSXTC
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $-579.6K | ||
| Q2 23 | — | — | ||
| Q3 22 | — | $-549.1K | ||
| Q2 22 | — | — |
自由现金流AZNSXTC
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
自由现金流率AZNSXTC
| Q3 25 | — | -216.2% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
资本支出强度AZNSXTC
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
